ILMN
Illumina IncHealth Careinsider_universeEverything we've seen
- ?Nov 13, 7:30 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- !Nov 13, 7:30 PMsignalseverity 0.33
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- ?Nov 13, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- !Nov 13, 3:20 PMsignalseverity 0.33
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- ?Nov 13, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- !Nov 13, 3:20 PMsignalseverity 0.33
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- ?Nov 13, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- !Nov 13, 2:21 PMsignalseverity 0.33
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- ?Nov 13, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- !Nov 13, 2:21 PMsignalseverity 0.33
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- ?Nov 13, 1:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.22% with no attributable headline catalyst, suggesting either broad market pressure or quiet institutional selling. The macro context (T10Y2Y at 2.0σ below trend, a flattening/low-spread environment) is modestly negative for growth/biotech names like ILMN, as a flatter curve can compress risk appetite for high-multiple equities. However, without a clear news driver, the move could be purely technical or sector-rotation-related. With 125 minutes remaining there is meaningful time for continuation, but no strong catalyst to accelerate the move further. Volume context is unknown and no reversal signal is evident. The setup is a plain momentum read — no strong reason to fade but equally no high-conviction continuation signal. Assigning baseline continuation probability at 0.5, just at the threshold.
- !Nov 13, 1:40 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ILMN is down 2.22% with no attributable headline catalyst, suggesting either broad market pressure or quiet institutional selling. The macro context (T10Y2Y at 2.0σ below trend, a flattening/low-spread environment) is modestly negative for growth/biotech names like ILMN, as a flatter curve can compress risk appetite for high-multiple equities. However, without a clear news driver, the move could be purely technical or sector-rotation-related. With 125 minutes remaining there is meaningful time for continuation, but no strong catalyst to accelerate the move further. Volume context is unknown and no reversal signal is evident. The setup is a plain momentum read — no strong reason to fade but equally no high-conviction continuation signal. Assigning baseline continuation probability at 0.5, just at the threshold.
- ?Nov 13, 1:23 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- !Nov 13, 1:23 PMsignalseverity 0.34
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- ?Nov 13, 1:23 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- !Nov 13, 1:23 PMsignalseverity 0.34
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- ?Nov 13, 12:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.48% with 225 minutes remaining — a meaningful move with ample time for continuation. No headlines are present, but the absence of news doesn't disqualify the move; real institutional flow often precedes or operates without public catalysts. The macro context (T10Y2Y at 2.0σ below 24-month trend) reflects a flattening yield curve environment, which is modestly supportive of defensive or growth-sensitive names like ILMN in a risk-off tone — this doesn't strongly argue for a reversal. However, the macro context is not a clear tailwind for further selling either; a flat/flattening curve can support longer-duration equities and may provide a mild headwind to the downside continuation. With no strong directional catalyst confirmed, no volume data to confirm conviction, and a move that sits at the lower end of the 'meaningful' threshold (2.48%), this is an ordinary momentum setup. The time remaining is substantial, keeping the trade viable, but the evidence quality is modest. Assigning a slight lean toward continuation given the established downward flow and time remaining, but not with high conviction.
- !Nov 13, 12:01 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ILMN is down 2.48% with 225 minutes remaining — a meaningful move with ample time for continuation. No headlines are present, but the absence of news doesn't disqualify the move; real institutional flow often precedes or operates without public catalysts. The macro context (T10Y2Y at 2.0σ below 24-month trend) reflects a flattening yield curve environment, which is modestly supportive of defensive or growth-sensitive names like ILMN in a risk-off tone — this doesn't strongly argue for a reversal. However, the macro context is not a clear tailwind for further selling either; a flat/flattening curve can support longer-duration equities and may provide a mild headwind to the downside continuation. With no strong directional catalyst confirmed, no volume data to confirm conviction, and a move that sits at the lower end of the 'meaningful' threshold (2.48%), this is an ordinary momentum setup. The time remaining is substantial, keeping the trade viable, but the evidence quality is modest. Assigning a slight lean toward continuation given the established downward flow and time remaining, but not with high conviction.
- ?Nov 13, 11:36 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- !Nov 13, 11:36 AMsignalseverity 0.34
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- ?Nov 13, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.62% intraday with no specific news catalyst identified, suggesting this is flow-driven selling rather than a reaction to a discrete event. The move is meaningful but not extreme. With 320 minutes remaining (well over half the trading day left), there is ample time for the move to continue or reverse. The macro context shows a compressed T10Y2Y spread (2.0σ below trend), which modestly favors defensives and pressures growth/biotech-adjacent names like ILMN — a mild tailwind for continued downside. No reversal signal is evident (no fade-off-lows pattern described), and absence of news does not disqualify momentum. However, without a clear catalyst or volume confirmation, conviction is limited. The setup clears the 0.5 threshold narrowly: modest continuation pressure from macro context, ample time remaining, and no contradicting reversal signal. Probability set at 0.52 — take the trade with tight stop discipline per system rules.
- !Nov 13, 10:25 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
ILMN is down 2.62% intraday with no specific news catalyst identified, suggesting this is flow-driven selling rather than a reaction to a discrete event. The move is meaningful but not extreme. With 320 minutes remaining (well over half the trading day left), there is ample time for the move to continue or reverse. The macro context shows a compressed T10Y2Y spread (2.0σ below trend), which modestly favors defensives and pressures growth/biotech-adjacent names like ILMN — a mild tailwind for continued downside. No reversal signal is evident (no fade-off-lows pattern described), and absence of news does not disqualify momentum. However, without a clear catalyst or volume confirmation, conviction is limited. The setup clears the 0.5 threshold narrowly: modest continuation pressure from macro context, ample time remaining, and no contradicting reversal signal. Probability set at 0.52 — take the trade with tight stop discipline per system rules.
- ?Nov 12, 7:30 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- !Nov 12, 7:30 PMsignalseverity 0.32
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- ?Nov 12, 2:36 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- !Nov 12, 2:36 PMsignalseverity 0.32
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- ?Nov 12, 10:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.35% intraday with no attributable news catalyst. The move represents real institutional flow and modest directional conviction. Macro context shows the 10Y inflation breakeven (T10YIE) printing 1.7σ below trend, which signals subdued inflation expectations — broadly supportive of long-duration/growth assets like ILMN (a genomics/biotech name), creating a mild macro headwind against further downside continuation. However, this is a relatively muted macro tailwind that may not be enough to reverse a move of this size. With 290 minutes remaining (nearly a full session still ahead), there is ample time for the move to either continue or reverse. No news catalyst means the driver is likely flow-based or technical, which can persist but also fade. The absence of a clear reversal signal, combined with the size of the move crossing the 2% threshold, gives modest evidence of continuation. Probability sits just above the neutral threshold — slight lean toward continued downside but without conviction, given the macro context mildly opposing it.
- !Nov 12, 10:55 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
ILMN is down 2.35% intraday with no attributable news catalyst. The move represents real institutional flow and modest directional conviction. Macro context shows the 10Y inflation breakeven (T10YIE) printing 1.7σ below trend, which signals subdued inflation expectations — broadly supportive of long-duration/growth assets like ILMN (a genomics/biotech name), creating a mild macro headwind against further downside continuation. However, this is a relatively muted macro tailwind that may not be enough to reverse a move of this size. With 290 minutes remaining (nearly a full session still ahead), there is ample time for the move to either continue or reverse. No news catalyst means the driver is likely flow-based or technical, which can persist but also fade. The absence of a clear reversal signal, combined with the size of the move crossing the 2% threshold, gives modest evidence of continuation. Probability sits just above the neutral threshold — slight lean toward continued downside but without conviction, given the macro context mildly opposing it.
- ?Nov 12, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- !Nov 12, 10:20 AMsignalseverity 0.33
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN has dropped 33.3% from its 30-day high with no available news headlines to explain the catalyst, and the 10-Q/8-K filings contain no extractable metrics to assess fundamental condition. The drop is notably idiosyncratic — the Health Care sector (XLV) is actually a top performer over the past 30 days (+12.56pts vs SPY), suggesting this is company-specific selling rather than a sector-wide pullback. This idiosyncratic weakness without an identifiable recovery catalyst is a significant concern. Options flow is below average in both calls and puts (both z-scores negative), indicating no unusual informed buying interest on the dip. A director-level insider (Keith Meister) sold ~$2.47M worth of shares near the dip, which is a meaningful negative signal. The only positives are earnings 83 days away (non-factor) and ILMN's status as a leading genomics platform that remains financially sound in the long run.
- ?Nov 12, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- !Nov 12, 10:20 AMsignalseverity 0.33
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 33.3% from its 30-day high, a large drop that would ordinarily be a strong mean-reversion candidate. However, the signal stack is weak: no cluster insider buys (the insider activity is dominated by a large director sale of ~$2.5M by Keith Meister and routine tax-related F-transactions), options flow is modestly put-leaning (P/C ratio 1.11), and VIX is at the 76th percentile (elevated, -1). The sector (Health Care) is actually outperforming SPY strongly over 30 days (+12.56pts), making this a single-stock idiosyncratic drop rather than a sector-wide dip (-1). The 10Y yield at 4.88% is a structural headwind for a long-duration growth biotech name (-1). The 10-Q and 8-K filings lack disclosed metrics, so no fundamental deterioration is confirmed, but no positive catalyst is visible either.
- ?Nov 12, 9:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down ~3.18% intraday with no attributable headline, suggesting institutional flow or technical selling rather than a news-driven spike that might quickly reverse. The move is meaningful in magnitude and represents real conviction. Macro context shows 10Y inflation breakevens 1.7σ below trend (T10YIE at 2.2), which is a low-inflation/low-rate environment that is not particularly hostile to long-duration growth names like ILMN — this slightly softens the bearish case but doesn't reverse it. With 365 minutes remaining (essentially a full trading day ahead), there is ample time for continuation if the selling pressure persists. No reversal signal (e.g., intraday fade back through key levels) is evident from the data provided. The absence of news is not a disqualifier — large unexplained moves often reflect pre-positioned institutional activity that continues into the close. However, the macro backdrop (falling real rates environment) is modestly supportive of biotech/genomics names, capping the continuation probability. Overall, slight lean toward continuation of the downside move, but without strong corroborating evidence (volume data, sector peers, clear catalyst), this is a borderline read at 0.52.
- !Nov 12, 9:40 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
ILMN is down ~3.18% intraday with no attributable headline, suggesting institutional flow or technical selling rather than a news-driven spike that might quickly reverse. The move is meaningful in magnitude and represents real conviction. Macro context shows 10Y inflation breakevens 1.7σ below trend (T10YIE at 2.2), which is a low-inflation/low-rate environment that is not particularly hostile to long-duration growth names like ILMN — this slightly softens the bearish case but doesn't reverse it. With 365 minutes remaining (essentially a full trading day ahead), there is ample time for continuation if the selling pressure persists. No reversal signal (e.g., intraday fade back through key levels) is evident from the data provided. The absence of news is not a disqualifier — large unexplained moves often reflect pre-positioned institutional activity that continues into the close. However, the macro backdrop (falling real rates environment) is modestly supportive of biotech/genomics names, capping the continuation probability. Overall, slight lean toward continuation of the downside move, but without strong corroborating evidence (volume data, sector peers, clear catalyst), this is a borderline read at 0.52.
- ?Nov 12, 9:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 12, 9:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 12, 9:20 AMsignalseverity 0.31
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 12, 9:20 AMsignalseverity 0.31
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 11, 7:31 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- !Nov 11, 7:31 PMsignalseverity 0.31
Agent 4 — Dip Buyer (Frozen) — dip_skipped
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- ?Nov 11, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 11, 2:21 PMsignalseverity 0.30
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 11, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 11, 2:20 PMsignalseverity 0.30
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 11, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 11, 1:20 PMsignalseverity 0.29
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 11, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 11, 1:20 PMsignalseverity 0.29
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 11, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 11, 12:20 PMsignalseverity 0.29
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 11, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 11, 12:20 PMsignalseverity 0.29
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 11, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 11, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 11, 10:21 AMsignalseverity 0.29
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 11, 10:21 AMsignalseverity 0.29
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 11, 9:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- !Nov 11, 9:21 AMsignalseverity 0.31
Agent 5 — Dip Buyer (Evolving) — dip_skipped
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 11, 9:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- !Nov 11, 9:21 AMsignalseverity 0.31
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 10, 7:31 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ILMN is down 31.1% from its 30-day high, but there are no news headlines or clearly substantive SEC filing metrics in the evidence window to explain a company-specific deterioration event such as a guidance cut, fraud, or accounting issue. The 10-Q and 8-K filings are present but contain no extracted metrics, making it impossible to confirm financial health with precision; however, Illumina remains the dominant genomic sequencing platform with a broadly sound long-term business model. The macro context (elevated mortgage rates) is not directly relevant to ILMN's business, offering neither a tailwind nor a headwind specific to genomics instrumentation.
- ?Nov 10, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 10, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 10, 2:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.50% intraday with no attributable headlines, suggesting this is likely flow-driven rather than news-driven. The macro context (elevated DFF at 2.0σ above trend) points to a higher-rate environment which modestly pressures growth/genomics names like ILMN, providing a mild tailwind for continued selling. However, with 90 minutes remaining, there is meaningful time for either continuation or mean reversion. The absence of a catalyst or clear sector catalyst makes this a borderline read. No reversal signals are evident from the data provided, and a 2.5% move does represent real conviction selling. With the system's bounded risk profile and the absence of a specific reason to expect a fade, a marginal continuation call is warranted, but confidence is limited — assigning exactly 0.50 to reflect genuine uncertainty with a slight lean toward continued downside pressure given the macro backdrop.
- ?Nov 10, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 10, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 10, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 10, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 10, 12:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 2.79% intraday with no attributable headline catalyst, suggesting either institutional distribution or sector-level pressure. The move is at the lower boundary of the 2-5% 'meaningful flow' range, indicating some conviction but not an overwhelming force. Macro context shows elevated DFF (3.88, 2.0σ above trend), which is marginally negative for growth/biotech names like ILMN as higher rates compress multiples and discount rates rise — this provides a mild tailwind for continued downside. With 220 minutes remaining there is ample time for continuation or reversal, so time is not a limiting factor. No reversal signals are evident (no fade off lows, no headline-driven bounce catalyst). The absence of news does not disqualify momentum. Net assessment: modest continuation bias to the downside with no strong reason to expect a sharp reversal, but conviction is limited given the lack of a clear catalyst and the relatively modest move size. Probability set just above the 0.5 threshold reflecting ordinary momentum without strong amplifying factors.
- ?Nov 10, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 10, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 9, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 9, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 9, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 9, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 9, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 9, 10:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 9, 9:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 32.9% from its 30-day high with no news headlines, no insider buying, and no options flow to explain or support the move. The 10-Q and 8-K filings lack extracted metrics, making fundamental assessment impossible. Critically, today's broad market is under severe stress (QQQ -5.88%, SPY -3.99%, VXX +27.02%), suggesting this drop is at least partly macro-driven. However, the sector context is a significant negative signal: Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN is falling sharply even as its sector outperforms — pointing to idiosyncratic, company-specific selling pressure of unknown origin. This idiosyncratic weakness without an identifiable catalyst is a material red flag.
- ?Nov 9, 9:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ?Nov 9, 6:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
ILMN is down 32.9% from its 30-day high with no visible fundamental catalyst in the SEC filings (metrics are empty/unreadable) and no news headlines to explain the drop, suggesting macro/market-wide pressure may be a factor. However, the broader market is in acute selloff today (SPY -3.99%, QQQ -5.88%, VIX spiking with VXX +26.41%), which introduces significant systematic risk. Critically, Health Care (XLV) is the top-ranked sector with strong 30-day relative strength (+12.53pts vs SPY), meaning ILMN's 32.9% drop is idiosyncratic relative to its own sector — a meaningful negative signal indicating a single-stock problem rather than sector-wide weakness.
- ❖Oct 30, 6:49 AMnewsvia finnhub
Will TXG Stock Ever Get Back To Its Old High?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 30, 6:43 AMnewsvia finnhub
Dow Jones Futures: Nasdaq Futures Plunge 2% On Amazon, Intel After Google, ServiceNow, Fortinet Dive
Amazon, Intel and Illumina were earnings losers overnight after Google, ServiceNow and Fortinet slammed techs. Much of the market is doing fine.
- ❖Oct 29, 9:55 PMnewsvia finnhub
Dow Jones Futures Fall, Nasdaq Futures Plunge 2% On Amazon, Intel After Google, ServiceNow, Fortinet Dive
Amazon, Intel and Illumina were earnings losers overnight after Google, ServiceNow and Fortinet slammed techs. Much of the market is doing fine.
- ▣Oct 29, 8:00 PMjournalstop
Agent 4 — Dip Buyer (Frozen) closed long 3 @ $246.50 (-$74.19)
intraday stop sweep
- ❖Oct 29, 7:30 PMnewsvia finnhub
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- ❖Oct 29, 6:14 PMnewsvia finnhub
Illumina Q3 Earnings Call Highlights
Illumina (NASDAQ:ILMN) reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they rem
- ❖Oct 29, 6:06 PMnewsvia finnhub
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall
S&P 500 after-hours movers: Mondelez International and FedEx Freight were among gainers, while Intel and Reddit were among decliners after today's U.S. session.
- ❖Oct 29, 5:59 PMnewsvia finnhub
Illumina shares tumble 12% despite earnings beat on China woes
Investing.com -- Illumina Inc (NASDAQ:ILMN) reported third-quarter results that exceeded analyst expectations, but shares tumbled 12% in after-hours trading Thursday as investors focused on the company's China revenue challenges.
- ❖Oct 29, 5:58 PMnewsvia finnhub
Dow Jones Futures: Amazon, Intel Lead Earnings Losers After Google, ServiceNow, Fortinet Hit Nasdaq
Amazon, Intel and Illumina were earnings losers overnight after Google, ServiceNow and Fortinet slammed techs. Much of the market is doing fine.
- ❖Oct 29, 5:30 PMnewsvia finnhub
Illumina (NASDAQ:ILMN) Q3 Revenue Miss Overshadows EPS Beat
Illumina Q3 EPS beat estimates but revenue missed, sending ILMN shares lower after hours as sales growth concerns outweighed profit upside.
- ❖Oct 29, 4:35 PMnewsvia finnhub
Illumina (ILMN) Q3 Earnings Beat Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +5.88% and -0.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Oct 29, 4:15 PMnewsvia finnhub
Illumina (NASDAQ:ILMN) reports sales below analyst estimates in Q3 2026 earnings, stock drops 16%
Genomics company Illumina (NASDAQ:ILMN) missed Wall Street’s revenue expectations in Q3 2026 as revenue rose 4.2% year on year to $1.13 billion. On the other hand, the company’s full-year revenue guidance of $4.65 billion at the midpoint came in 0.6% above analysts’ consensus estimates. Its non-GAAP profit of $1.44 per share was 6.1% above analysts’ consensus estimates.
- ❖Oct 29, 4:12 PMnewsvia finnhub
Illumina: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Illumina Inc. (ILMN) on Thursday reported third-quarter net income of $220 million.
- ❖Oct 29, 4:05 PMnewsvia finnhub
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026.
- ❖Oct 29, 3:28 PMnewsvia finnhub
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
Illumina, Inc. (ILMN) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDTCompany ParticipantsConor Noel McNamara - VP of Investor RelationsJacob Thaysen -...
- ❖Oct 29, 11:27 AMnewsvia finnhub
Single-Cell eQTL Clinical Workflows Market Forecast to Reach $4.51 Billion by 2030 | Capitalize on 19.9% CAGR with Illumina, QIAGEN, 10x Genomics, Singleron and More
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Single-Cell Expression Quantitative Trait Locus (EQTL) Clinical Workflows Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-cell expression quantitative trait locus (eQTL) clinical workflows market is experiencing rapid expansion as healthcare and life sciences organizations increase their investment in high-resolution genomic analysis. The market grew from $1.82 billion in 2025 to $2.18 billion in 2026, r
- ❖Oct 29, 11:26 AMnewsvia finnhub
Slide-DNA-Sequencing for Copy Number Mapping Global Market Report 2026 | Capitalize on AI and Spatial Genomics with Illumina, 10x Genomics and BGI Genomics
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Slide-Deoxyribonucleic Acid (DNA)-Sequencing for Copy Number Mapping Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping market is experiencing rapid growth, supported by advances in genomic research, precision medicine, high-throughput imaging, and molecular diagnostics. The market is projected to increase from $0.38 billion in 2025 to $0.43 bill
- ❖Oct 29, 11:25 AMnewsvia finnhub
Global Bead-Linked Transposase Library Kits Market Report 2026 | Capitalize on 11.6% CAGR Through 2030 as Illumina, Thermo Fisher, Roche, and Agilent Scale AI-Automated Sequencing
Profiles Roche, Thermo Fisher, Eurofins, Agilent and Illumina, covering bead-linked transposase kits for streamlined DNA/RNA sequencing-library preparationDublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Bead-Linked Transposase Library Kits Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bead-linked transposase library kits market is experiencing rapid growth as next-generation sequencing expands across genomics research, clinical diagnostics, drug developmen
- ❖Oct 29, 11:23 AMnewsvia finnhub
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market Report 2026 | Capitalize on 14.9% CAGR as Roche, Illumina, QIAGEN and Pangea Scale AI-Driven Liquid Biopsies
Company profiles cover urine tumor DNA testing products, technologies, applications and market activity.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global urine tumor deoxyribonucleic acid (DNA) testing market is experiencing rapid growth, supported by the increasing prevalence of urological cancers and rising demand for non-invasive cancer detection and monitoring.
- ❖Oct 29, 11:22 AMnewsvia finnhub
Global Viral Genome Sequencing Market 2026: Size, Trends, Forecast to 2030 | Capitalize on AI and Real-Time Monitoring with Illumina, Thermo Fisher, Oxford Nanopore, and PacBio
Viral Genome Sequencing Market to Reach $13.57 Billion by 2030 as Genomic Surveillance ExpandsDublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Viral Genome Sequencing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global viral genome sequencing market is experiencing rapid growth as healthcare systems, research institutions and public health agencies increase investments in infectious disease surveillance. The market is projected to grow from $6.71 billion in 2025
- ❖Oct 29, 10:39 AMnewsvia finnhub
Global Shotgun Metagenomics Clinical Reporting Market Report 2026 | Capitalize on 16.7% CAGR as Illumina, Karius, QIAGEN and Oxford Nanopore Accelerate AI Diagnostics
Profiles BaseClear, BGI Genomics, BugSeq, Illumina and Karius, covering shotgun metagenomics clinical reporting solutions and competitive activity.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Shotgun Metagenomics Clinical Reporting Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global shotgun metagenomics clinical reporting market is experiencing rapid growth as healthcare organizations increase their use of advanced genomic testing for infectious disease diagn
- ❖Oct 29, 10:38 AMnewsvia finnhub
Global Long-Read Metagenomics Market Report 2026 | Capitalize on 21.3% CAGR: Illumina, PacBio, Oxford Nanopore, QIAGEN, and BGI Genomics Accelerate AI Diagnostics
Boost ROI with AI-driven analysis, automated high-throughput prep, scalable sequencing, lower bioinformatics costs, and partnerships that improve accuracy and speed.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Long-Read Metagenomics Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global long-read metagenomics market is experiencing exponential growth, supported by advances in sequencing technology, microbiome research and genomic analytics. The market is project
- ❖Oct 29, 10:34 AMnewsvia finnhub
Global Pan-Ethnic Carrier Screening Programs Market Report 2026 | Capitalize on 14.1% CAGR as Illumina, Natera, Fulgent Genetics and LabCorp Scale AI and Multi-Gene Panels
Boost ROI via expanded gene panels, AI interpretation, tele-genetic counseling, routine prenatal integration and local reagent production to cut costs and widen access.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Pan-Ethnic Carrier Screening Programs Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global pan-ethnic carrier screening programs market is experiencing rapid growth as healthcare systems expand access to genetic testing across diverse populations. The
- ❖Oct 29, 10:32 AMnewsvia finnhub
Global Population Genomic Screening Programs Market Report 2026 | Capitalize on 14.6% CAGR to 2030 as Illumina, Roche, Thermo Fisher and Natera Scale AI and Precision Medicine
Boost ROI via AI interpretation, EHR integration, expanded screening, personalized prevention, and local manufacturing to offset tariffs.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Population Genomic Screening Programs Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global population genomic screening programs market is experiencing rapid growth, supported by advances in sequencing technologies, greater awareness of hereditary diseases and expanding public heal
- ❖Oct 29, 10:31 AMnewsvia finnhub
Sequencer as a Service Global Market Report 2026 | Capitalize on 20% CAGR to $5.73 Billion by 2030 as Illumina, BGI Genomics, Eurofins and Novogene Scale AI and Cloud Genomics
Boost ROI via pay-per-use cloud sequencing, automation, AI bioinformatics and outsourcing to reduce capital costs, scale capacity and accelerate results.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Sequencer as a Service Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global sequencer as a service market is experiencing rapid expansion as healthcare organizations, research institutes, biotechnology companies, and pharmaceutical developers seek flexible access to
- ❖Oct 29, 10:15 AMnewsvia finnhub
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share
BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. I rate BLLN stock as Buy.
- ❖Oct 28, 11:50 PMnewsvia finnhub
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
Explore why the fund outperformed the Russell 2500 despite a 4.75% decline, with key winners, laggards, and performance insights.
- ❖Oct 28, 12:00 PMnewsvia finnhub
Microarray Scanners - Global Strategic Business Report 2026: Capitalize on $1.6 Billion Industry Revenue by 2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina, and Bio-Rad Laboratories Dominate
Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Microarray Scanners - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global microarray scanners market was valued at US$986.1 million in 2025 and is projected to reach US$1.6 billion by 2032, advancing at a compound annual growth rate (CAGR) of 7.2%. Market expansion is being supported by growing investment in genomics, precision medicine, molecular diagnostics, pharmaceutical research and high-throughput biol
- ❖Oct 28, 11:30 AMnewsvia finnhub
Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test
Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck, Caterpillar and Shell report
- ❖Oct 28, 8:15 AMnewsvia finnhub
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- ❖Oct 28, 7:56 AMnewsvia finnhub
Can You Still Buy Tempus AI Stock Today?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 28, 7:30 AMnewsvia finnhub
Breakout Watch: 4 Reasons To Monitor This Top-Rated Medical Stock
A best-possible 99 Composite Rating is just one reason to watch Medpace stock. Here are four more telltale clues to monitor.
- ❖Oct 28, 5:10 AMnewsvia finnhub
What to expect from Illumina’s (ILMN) Q3 earnings
Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what you need to know.
- ❖Oct 28, 2:10 AMnewsvia finnhub
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
This report highlights the Q3 2026 performance contributors and portfolio changes for the Brown Advisory Flexible Equity Strategy. Read the full analysis now.
- ▢Oct 27, 8:00 PMjournal
Agent 7 — Day Trader opened long 10 @ $291.09
- ▣Oct 27, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 10 @ $289.01 (-$20.80)
EOD forced close — day trader never carries overnight
- ❖Oct 27, 4:05 PMnewsvia finnhub
Illumina To Webcast Upcoming Investor Conference
Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:
- ❖Oct 26, 10:36 AMnewsvia finnhub
Global DNA Sequencing in Drug Discovery Market Report 2026 | Capitalize on 12.5% CAGR as Illumina, Thermo Fisher, QIAGEN, and Oxford Nanopore Accelerate AI-Driven Precision R&D
Boost ROI through lower-cost assays, AI-driven analysis, local consumables production, supplier diversification, multiomics, and pharma-biotech partnerships.Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery Market Report 2026" has been added to ResearchAndMarkets.com's offering. DNA Sequencing in Drug Discovery Market to Reach $15.22 Billion by 2030 as Precision Medicine Advances The global deoxyribonucleic acid (DNA) sequencing in drug discovery
- ❖Oct 26, 8:47 AMnewsvia finnhub
What Happens To Tempus AI Stock If Its Cash Burn Continues?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 23, 1:36 PMnewsvia finnhub
Should Illumina Stock Holders Look At Thermo Fisher Instead?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 23, 10:25 AMnewsvia finnhub
How Investors May Respond To Illumina (ILMN) BioInsight AI Rollout
Illumina has rolled out three early access capabilities on its BioInsight Platform: Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts, to help researchers connect sequencing, analysis, and large scale genomic datasets more efficiently. The focus on AI driven variant prioritization and cohort level analysis indicates that Illumina is placing more emphasis on software and data workflows rather than relying only on instruments and consumables. The key question now is how...
- ❖Oct 23, 10:05 AMnewsvia finnhub
NGS Kits Market Forecasts Growth from $6.84 Billion (2025) to $19.36 Billion by 2036, Profiling Illumina, Thermo Fisher Scientific, Roche, Oxford Nanopore & 11 Other Key Players
201-Page Report Finds Library Preparation Leads and Long-Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow AdoptionDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "NGS Kits Market: Focus on Workflow, Sequencing Type, Application, End User, and Regional Analysis - Analysis and Forecast Year, 2026-2036" has been added to ResearchAndMarkets.com's offering. The global NGS kits market was valued at $6,843.4 m
- ❖Oct 23, 8:30 AMnewsvia finnhub
Here’s How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 4.59% on an annualized basis producing an average annual return of 13.52%. Currently, Illumina has a market capitalization of $43.25 billion.
- ❖Oct 22, 4:33 PMnewsvia finnhub
Twist Bioscience Sinks 9%, Illumina Down 5% as AI and Genomics Stocks Slide
Key TakeawaysTwist Bioscience shares fell 9% today with no company news, as Illumina dropped 5% in a broad selloff in tech and AI stocks. Twist’s run since mid-September came from AI deals and an analyst’s AI call, so the stock now moves with how investors feel about AI.
- ❖Oct 22, 9:00 AMnewsvia finnhub
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- ❖Oct 22, 7:45 AMnewsvia finnhub
ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.
- ❖Oct 22, 7:40 AMnewsvia finnhub
Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?
HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.
- ❖Oct 21, 3:06 PMnewsvia finnhub
S&P 500 Top Movers: Oct. 21, 2026 US Session
S&P 500 top movers on Oct. 21, 2026: CRL, SMCI and BE led gainers, while T, CMG and DXCM led decliners in the US session.
- ❖Oct 21, 12:36 PMnewsvia finnhub
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers
S&P 500 top movers for Oct. 21, 2026: Supermicro rose 9.18% among gainers, while Dexcom fell 6.22% among losers.
- ❖Oct 21, 12:23 PMnewsvia finnhub
How Long Can GeneDx Keep Burning Cash?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 21, 11:43 AMnewsvia finnhub
Stock Market Today: Nasdaq Vaults On SpaceX Report; Software Names Gain (Live Coverage)
The Nasdaq rallies Wednesday as SpaceX stock surges on earnings. Meta and Tesla are set to report late.
- ❖Oct 21, 11:34 AMnewsvia finnhub
Illumina’s (ILMN) Strong Quarterly Beats on Revenue and Earnings Drive Share Gains
Calamos Investments, a diversified global asset management firm, released its third-quarter 2026 investor letter for “Calamos Global Equity Fund”. A copy of the letter can be downloaded here. The fund returned 16.57% YTD, outperforming the MSCI World Index and the Morningstar Global Large-Stock Growth category. The fund views the quarterly rotation in AI leadership as […]
- ❖Oct 21, 9:15 AMnewsvia finnhub
Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale. DRAGEN Ultra extends genomic analysis beyond variant calling, using Illumina AI models and knowledge resources to prioritize candidate variants, and sort large numbers of research s
- ▢Oct 12, 8:00 PMjournal
Agent 4 — Dip Buyer (Frozen) opened long 3 @ $271.23
- ▣Oct 6, 8:00 PMjournalstop
Agent 2 — Adaptive closed long 72 @ $267.95 (+$3,861.24)
Long trailing stop: close $267.95 ≤ trailing floor $273.13 (peak × 0.93)
- ▢Oct 4, 8:00 PMjournal
Agent 7 — Day Trader opened long 10 @ $282.00
- ▣Oct 4, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 10 @ $291.79 (+$97.85)
Long target: close $291.79 ≥ target $290.46
- ▢Sep 23, 8:00 PMjournal
Agent 7 — Day Trader opened long 11 @ $265.47
- ▣Sep 23, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 11 @ $273.62 (+$89.65)
Long target: close $273.62 ≥ target $273.43
- ▢Sep 10, 8:00 PMjournal
Agent 2 — Adaptive opened long 72 @ $214.32
- ▣Aug 6, 8:00 PMjournalstop
Agent 2 — Adaptive closed long 91 @ $188.03 (+$1,828.62)
Long trailing stop: close $188.03 ≤ trailing floor $190.74 (peak × 0.93)
- ▣Aug 2, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 26 @ $198.30 (+$374.66)
52-Week High monthly rebalance. Position dropped from top 20.
- ▢Jul 29, 8:00 PMjournal
Agent 7 — Day Trader opened long 14 @ $198.47
- ▣Jul 29, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 14 @ $203.64 (+$72.38)
EOD forced close — day trader never carries overnight
- ▢Jul 1, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 26 @ $183.89
- ▢Jun 9, 8:00 PMjournal
Agent 2 — Adaptive opened long 91 @ $167.94
- ▣Jun 7, 8:00 PMjournalmanual
options_momentum closed long 70 @ $18.10 (+$790.03)
Stop: premium $14.25 ≤ trailing floor $16.67 (peak $22.22 × 0.75)
- ▣Jun 7, 8:00 PMjournalmanual
options_momentum closed long 30 @ $6.89 (+$2.03)
Stop: premium $5.26 ≤ trailing floor $8.11 (peak $10.81 × 0.75)
- ▣Jun 7, 8:00 PMjournalstop
options_momentum closed long 70 @ $10.96 (+$229.92)
Stop: premium $10.96 ≤ trailing floor $16.67 (peak $22.22 × 0.75)
- ▣May 31, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 23 @ $164.47 (+$34.04)
52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.
- ▣May 28, 8:00 PMjournaltarget
options_momentum closed long 30 @ $15.99 (+$249.66)
De-risk: premium $15.99 ≥ 2.0× entry $7.67. Selling 30/100 contracts; trailing the remainder.
- ▢May 28, 8:00 PMjournal
Agent 7 — Day Trader opened long 11 @ $158.70
- ▣May 28, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 11 @ $163.49 (+$52.69)
Long target: close $163.49 ≥ target $163.46
- ▢May 28, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 23 @ $162.99
- ▢May 28, 8:00 PMjournal
options_momentum opened long 70 @ $6.82
- ▢May 28, 8:00 PMjournal
options_momentum opened long 30 @ $6.82
- ▢May 27, 8:00 PMjournal
Agent 7 — Day Trader opened long 12 @ $156.03
- ▣May 27, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 12 @ $157.33 (+$15.66)
EOD forced close — day trader never carries overnight
- ▢May 26, 8:00 PMjournal
options_momentum opened long 30 @ $7.67
- ▢May 26, 8:00 PMjournal
options_momentum opened long 70 @ $7.67